More participants in the semaglutide group achieved weight reduction at 68 weeks
5% or more
10% or more
15% or more
P <0.001 for all three comparisons of odds
Change in body weight from baseline to week 68
Semaglutide: −15.3 kg
Placebo: −2.6 kg
Estimated treatment difference: −12.7 kg (95% CI, −13.7 to −11.7)
Participants who received semaglutide had
Greater improvement with respect to cardiometabolic risk factors
Greater increase in participant-reported physical functioning from baseline
Side effects of Semaglutide
Primarily nausea and diarrhea
Typically transient and mild-to-moderate in severity and subsided with time
More participants in the semaglutide group discontinued treatment owing to GI events vs placebo (4.5% vs 0.8%)
Semaglutide plus lifestyle interventions resulted in sustained weight loss in non-diabetic individuals
The authors conclude
…that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained, clinically relevant mean weight loss of 14.9%, with 86% of participants attaining at least 5% weight loss
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan